A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home